

# Table of Contents

## Preface — V

Sreekanth Thota

- 1 Overview of chemical drug design — 1**
- 1.1 Drug design — 1
- 1.2 Rational drug design — 2
- 1.3 Ligand-based drug design — 5
- 1.4 Structure-based drug design — 6
- 1.5 Pharmacophore-based approaches — 8
- 1.6 Structure-based approaches — 8
- 1.7 New lead generation — 8
- 1.8 Structure evaluation — 9
- 1.9 Future directions — 9

Meenakshi Rajpoot, Rajasri Bhattacharyya, Girish Kumar Gupta, Anil K. Sharma

- 2 Drug designing in novel drug discovery: Trends, scope and relevance — 15**
- 2.1 Introduction — 15
- 2.2 Drug designing — 16
- 2.3 Applications of SBDD — 24
- 2.4 Applications of LBDD — 25
- 2.5 Role of cheminformatics in drug discovery — 26
- 2.6 Conclusion — 26

Sumitra Nain, Garima Mathur, Girish Kumar Gupta, Sarvesh Paliwal

- 3 Structure- and ligand-based approaches in drug designing — 31**
- 3.1 Drug discovery — 31
- 3.2 Drug design — 33
- 3.3 Drug designing techniques — 33
- 3.4 Quantitative Structure-Activity Relationship (QSAR) — 35
- 3.5 Physicochemical parameters — 35
- 3.6 Biological parameters — 44
- 3.7 Statistical terms in QSAR — 48

Luciana Scotti, Francisco J. B. Mendonça Júnior, Marcelo S. da Silva, Marcus T. Scotti

- 4 Drug design applied to natural products against neglected diseases — 53**
- 4.1 Natural products — 53
- 4.2 Medicinal chemistry — 56
- 4.3 Docking — 58
- 4.4 Neglected diseases — 59
- 4.5 Final considerations — 79

Manu Sharma

- 5 Natural product hybrid compounds as drug leads — 87**
- 5.1 Introduction — 87
- 5.2 Naturally occurring hybrids/conjugates of natural products — 88
- 5.3 Synthetic hybrids of whole natural products — 91
- 5.4 Conclusion — 102

Komarla Kumarachari Rajasekhar

- 6 Drug metabolism — 107**
- 6.1 Introduction — 107
- 6.2 Phase I Metabolic reactions — 108
- 6.3 Oxidative mechanisms — 114
- 6.4 Reductive reactions — 139
- 6.5 Hydrolytic reactions — 145
- 6.6 Phase II conjugation reactions — 148
- 6.7 Factors affecting drug metabolism — 156

Seema Patel and Girish Kumar Gupta

- 7 Mistletoe lectin: A promising cancer therapeutic — 165**
- 7.1 Introduction — 165
- 7.2 Anticancer potency of bacteria/plant lectins — 167
- 7.3 Anticancer potency of mistletoe and the underlying mechanisms — 168
- 7.4 Mistletoe lectins — 170
- 7.5 Future directions — 174
- 7.6 Concluding remarks — 175

Tamara Angelo and André São Pedro

- 8 Antipsychotics — 183**
- 8.1 Introduction — 183
- 8.2 History — 183
- 8.3 Etiology of schizophrenia and related psychoses — 184
- 8.4 Potential mechanism of action of antipsychotics — 185
- 8.5 Structure-activity relationships and pharmacology of the drugs — 186
- 8.6 Research into future treatments for schizophrenia and related psychoses — 194

Purna Sarup

- 9 Chemometric analysis: A novel tool for herbal drug analysis and designing — 199**
- 9.1 Introduction — 199
- 9.2 Experimental — 201
- 9.3 Data analysis and quality evaluation — 202

9.4 Results and discussion — 204

9.5 Conclusion — 212

Subash Chandra Sahoo, Ramesh Kataria and S.K. Mehta

**10 Copper and its complexes: A pharmaceutical perspectives — 215**

10.1 Introduction — 215

10.2 Source of dietetic copper — 217

10.3 Recommended concentration of copper for human diet — 217

10.4 Copper consumption and suggestions — 218

10.5 Mechanism of copper transport in humans — 218

10.6 Copper deficiency and symptoms — 219

10.7 Copper metabolism and major diseases — 220

10.8 Copper metabolism and hypothesized health problems — 223

10.9 Copper complexes as an emerging tool in pharmaceutical sciences — 231

10.10 Concluding remarks — 236

Sunil Kumar, Madhuri T. Patil, Ramesh Kataria, Deepak B. Salunke

**11 Thiazole: A privileged scaffold in drug discovery — 243**

11.1 Introduction — 243

11.2 Synthetic routes for the construction of the thiazole ring — 247

11.3 Thiazole as privileged scaffold in synthetic drugs — 252

11.4 Ritonavir — 252

11.5 Nitazoxanide — 259

11.6 Sulfathiazole — 260

11.7 Thiabendazole — 262

11.8 Fatostatin — 263

11.9 Dasatinib — 265

11.10 Tiazofurin — 267

11.11 CYC116 — 268

11.12 NCH-31 — 269

11.13 TAK-715 — 271

11.14 Meloxicam — 272

11.15 Nizatidine — 274

11.16 Famotidine — 275

11.17 Conclusion — 277

**Index — 283**